267643-79-8

Usage

Uses

Used in Medicinal Chemistry and Drug Design:
(3S)-1-(2-phenylethyl)pyrrolidin-3-amine is used as a structural component in the development of pharmaceutical agents. Its unique configuration and amine properties make it a valuable building block for designing new drugs with targeted therapeutic effects.
Used in Neuroscience Research:
In the field of neuroscience, (3S)-1-(2-phenylethyl)pyrrolidin-3-amine is employed as a research tool to study the interactions with neurotransmitter systems. This helps in understanding the molecular mechanisms underlying various neurological processes and disorders, potentially leading to the discovery of new treatments for neurological conditions.

Downstream Products

• 267643-80-1 (S)-N-(1-(2-phenylethyl)pyrrolidin-3-yl)diphenylacetamide 
• 1392473-70-9 1-(quinuclidin-3-yl)-3-((S)-1-(2-phenylethyl)pyrrolidin-3-yl)urea 
• 1348841-65-5 (S)-N-(1-(2-phenylethyl)pyrrolidin-3-yl)bis(pyridin-2-yl)acetamide 
• 1349484-80-5 (S)-N-(1-(2-phenylethyl)pyrrolidin-3-yl)-7-norbornanecarboxamide 
• 1392473-51-6 (S)-N-(1-(2-phenylethyl)pyrrolidin-3-yl)bicyclo[2.2.2]octane-1-carboxamide 

Relevant academic research and scientific papers

2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY

A compound of formula (I′) or (I′′) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

Pyrrolidine compounds and medicinal utilization thereof

The present invention provides a pyrrolidine compound of the formula (I) wherein each symbol is as defined in the specification, an optically active compound thereof and a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition containing a compound of the formula (I), an optically active compound thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. The compound of the present invention has a serotonin 2 receptor antagonistic action along with a platelet aggregation suppressive action, a peripheral circulation improving action and a lacrimation promoting action. Therefore, the compound of the present invention can be a useful medicine showing effect against thrombotic embolism, dry eye and the like.